About Revolution Medicines, Inc.
https://www.revmed.comRevolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors.
CEO
Mark A. Goldsmith
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 181
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Raymond James
Strong Buy
HC Wainwright & Co.
Buy
Needham
Buy
Goldman Sachs
Buy
Guggenheim
Buy
Stifel
Buy
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:15.66M
Value:$1.9B
FARALLON CAPITAL MANAGEMENT LLC
Shares:14.63M
Value:$1.77B
BLACKROCK INC.
Shares:13.41M
Value:$1.63B
Summary
Showing Top 3 of 360
About Revolution Medicines, Inc.
https://www.revmed.comRevolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $315.27M ▲ | $-305.21M ▼ | 0% | $-1.61 ▼ | $-289.44M ▼ |
| Q2-2025 | $0 | $264.71M ▲ | $-247.79M ▼ | 0% | $-1.31 ▼ | $-260.91M ▼ |
| Q1-2025 | $0 | $240.76M ▲ | $-213.42M ▼ | 0% | $-1.13 ▲ | $-237.04M ▼ |
| Q4-2024 | $0 | $216.31M ▲ | $-194.57M ▼ | 0% | $-1.13 ▼ | $-212.92M ▼ |
| Q3-2024 | $0 | $175.71M | $-156.29M | 0% | $-0.94 | $-153.41M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.93B ▼ | $2.25B ▼ | $655.02M ▲ | $1.6B ▼ |
| Q2-2025 | $2.14B ▲ | $2.43B ▲ | $564.2M ▲ | $1.87B ▼ |
| Q1-2025 | $2.1B ▼ | $2.37B ▼ | $287.2M ▼ | $2.08B ▼ |
| Q4-2024 | $2.29B ▲ | $2.56B ▲ | $293.1M ▲ | $2.27B ▲ |
| Q3-2024 | $1.55B | $1.76B | $196.69M | $1.57B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-305.21M ▼ | $-207.31M ▲ | $24.85M ▼ | $-1.59M ▼ | $-184.05M ▼ | $-210.66M ▲ |
| Q2-2025 | $-247.79M ▼ | $-221.76M ▼ | $34.28M ▲ | $256.58M ▲ | $69.1M ▲ | $-229.21M ▼ |
| Q1-2025 | $-213.42M ▼ | $-194.44M ▼ | $-15.95M ▲ | $874K ▼ | $-209.51M ▼ | $-197.7M ▼ |
| Q4-2024 | $-194.57M ▼ | $-138.29M ▼ | $-392.9M ▼ | $873.8M ▲ | $341.8M ▲ | $-139.51M ▼ |
| Q3-2024 | $-156.29M | $-130.42M | $-21.47M | $77.29M | $-74.59M | $-133.94M |
Revenue by Products
| Product | Q2-2022 | Q3-2022 | Q4-2022 | Q1-2023 |
|---|---|---|---|---|
 Collaboration Revenue Member | $10.00M ▲ | $0 ▼ | $20.00M ▲ | $10.00M ▼ |
CEO
Mark A. Goldsmith
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 181
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Raymond James
Strong Buy
HC Wainwright & Co.
Buy
Needham
Buy
Goldman Sachs
Buy
Guggenheim
Buy
Stifel
Buy
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:15.66M
Value:$1.9B
FARALLON CAPITAL MANAGEMENT LLC
Shares:14.63M
Value:$1.77B
BLACKROCK INC.
Shares:13.41M
Value:$1.63B
Summary
Showing Top 3 of 360